NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ), the single largest U.S. equity exchange by market share, announced during the month of January, a collection of new and transitioned listings to further solidify its place as a quality primary listing and trading venue for ETPs.
“Our expanding portfolio of ETP listings is highly reflective of our positive outlook for the product category in 2016 and beyond,” said Jeff McCarthy, Vice President and Head of ETP Listings at Nasdaq. “We are excited to build new and grow existing relationships with issuers who - in a growing trend - want diversification and are looking for leadership as part of their core risk-management strategies. Nasdaq is focused on engaging with market participants to advocate and create infrastructure to support an exchange traded product market.”
Nasdaq ETF Listing Highlights in January:
Nasdaq saw 12 transitions to its platform from competitive listing venues:
- BlackRock Inc. announced plans to switch the following 10 of its iShares ETFs to Nasdaq; the switches officially took place February 2, 2016:
- iShares 20+ Year Treasury Bond ETF (NASDAQ: TLT)
- iShares Asia 50 ETF (NASDAQ: AIA)
- iShares MSCI New Zealand Capped ETF (NASDAQ: ENZL)
- iShares MSCI Brazil Small-Cap ETF (NASDAQ: EWZS)
- iShares Global Infrastructure ETF (NASDAQ: IGF)
- iShares Core MSCI Total International Stock ETF (NASDAQ: IXUS)
- iShares Morningstar Mid-Cap Value ETF (NASDAQ: JKI)
- iShares MSCI China ETF (NASDAQ: MCHI)
- iShares MSCI EAFE Small-Cap ETF (NASDAQ: SCZ)
- iShares 0-5 Year Investment Grade Corporate Bond ETF (NASDAQ: SLQD)
- Van Eck announced it will change the primary listing venue for the following two funds to Nasdaq; the switches officially took place February 1, 2016:
- Market Vectors Biotech ETF (NASDAQ: BBH)
- Market Vectors Pharmaceutical ETF (NASDAQ: PPH)
Additionally, Nasdaq was the premier exchange of choice for five new ETF launches:
- Van Eck expanded its relationship with Nasdaq by listing a new product:
- Market Vectors Generic Drugs ETF (NASDAQ: GNRX)
- Legg Mason entered the ETF arena with its very first products:
- Legg Mason Developed ex-US Diversified Core ETF (NASDAQ: DDBI)
- Legg Mason Emerging Markets Diversified Core ETF (NASDAQ: EDBI)
- Legg Mason US Diversified Core ETF (NASDAQ: UDBI)
- Legg Mason Low Volatility High Dividend ETF (NASDAQ: LVHD)
In 2015, The Nasdaq Stock Market®, the single largest U.S. equity exchange by market share increased new ETF listings by approximately 43 percent and reached a total number of 219 listed ETFs, after adding 54 new listings that year. Of these funds, 19 represented transitioned funds from competitive exchanges and 18 represented index switches as well. For issuers who want to learn more about opportunities to list and grow on The Nasdaq Stock Market®, please visit our website or email firstname.lastname@example.org.
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
Nothing contained herein should be construed as investment advice from Nasdaq, either on behalf of a particular financial product or an overall investment strategy. Nasdaq makes no recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Investors should undertake their own due diligence and carefully evaluate financial products before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED